

# Press Release



## Participation in the compound sharing library business

---

**TOKYO, February 6th, 2020** – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced that it has reached an outsourcing contract agreement with CAC Croit Corporation (Head Office: Chuo-ku, Tokyo, President: Hajimu Kato, hereinafter "CAC Croit") regarding its compound library business program "QualityLead", that manages compound libraries\* and produces plate production.

The QualityLead is a program where CAC Croit provides an integrated platform for the management of compound libraries as well as plate production. Through this QualityLead program, we aim to reduce compound management related costs and hope that this compound library sharing platform will in the near future, be a platform system that provides the basis for a system in which pharmaceutical companies, academia and bio-venture companies can all utilize and share their compound libraries.

Through this outsourcing agreement with CAC Croit regarding the compound library management and platform production for conducting HTS\*\*, ASKA will strongly consider participating in the "compound sharing" through the QualityLead program.

By participating in the QualityLead program, we will seek to improve our productivity within R&D and continue to work toward our vision of being a "competitive specialty pharmaceutical company."

\*Compound library: Compounds for drug discovery purpose owned and managed by each company.

\*\*HTS (High Throughput Screening): A means to select a compound (hit compound) with a high affinity for a target molecule from a compound library, which is the starting point for drug discovery.

[About CAC Croit]

CAC Croit is a member of the CAC Group, which has approximately 20 group companies in Japan and overseas, and offers a high-quality, one-stop service that combines business support (CRO) and information technology (IT) to provide support for a speedy and efficient drug development. For more information, please visit <https://www.croit.com/en/>.